Eighty per cent more patients in 10 years of UK molecular radiotherapy: Internal Dosimetry Users Group survey results from 2007 to 2017

Bruno Rojas, Daniel R. McGowan, Matthew J. Guy, Jill Tipping, Matthew Aldridge and Jonathan Gear

Nuclear Medicine Communications 2019, 40:657–661

Introduction

The Internal Dosimetry Users Group has surveyed UK molecular radiotherapy (MRT) activity for cancer treatment in the UK. Data are presented here spanning 10 years of MRT activity across 31 UK centres, one from Northern Ireland, one from Wales, two from Scotland and 27 from England.

Results were compiled from a survey of 2007 activity by the British Institute of Radiology Molecular Radiotherapy Working Party [1], subsequent matched surveys by Internal Dosimetry Users Group of data from 2011, 2012, 2013, 2014 and 2015 which have previously been presented [2,3] and new data from 2016 and 2017. The 2011 and 2012 surveys were carried out online using a dedicated webpage and subsequent surveys were distributed by email, all being publicized widely within the nuclear medicine and medical physics communities. Centres were asked a range of questions about MRT but presented here are data on the number of patients and treatments for each therapy type, activity regimens and trial participation. Treatments identified were Na\(^{131}\)I radioiodine (RAI) for thyroid cancer, \(^{131}\)I-metaiodobenzylguanidine (\(^{131}\)I-mIBG) and peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs), \(^{89}\)Sr-chloride, \(^{153}\)Sm-EDTMP and \(^{223}\)Ra-chloride (Xofigo; Bayer, Leverkusen, Germany) for bone metastases, MRT for haematological malignancies and selective internal radionuclide therapy (SIRT) for liver metastases.

Results and discussion

Between 2007 and 2017 we have seen an 82% increase in the number of patients treated using MRT and a 250% increase in the number of MRT treatments administered as shown in Fig. 1. All 31 responding centres provided MRT to adults and nine centres to paediatric patients as shown in Table 1. A total of 24 centres participated in 28 MRT trials which are summarized in Table 2 using the trial short name where available and the clinical trial IDs from the European Union (https://www.clinicaltrialsregister.eu), USA (https://clinicaltrials.gov) or UK (http://www.isrctn.com) registries in brackets.

Incidences of thyroid cancer have risen steadily over the past decade, increasing by 47% between 2007 and 2015 [4].
Survey data on RAI for thyroid cancer are summarized in Fig. 2 and initially reflected the steady rise in incidence. However, treatment numbers peaked in 2012 before declining up until 2015. Since then total treatments, made up of ‘Ablation’ (referring to the first RAI treatment after thyroidectomy intending to ablate residual thyroid) and ‘Therapy’ (referring to any subsequent RAI treatment) in a relatively consistent balance, have risen again reaching their maximum in 2017 where 35% more treatments were given than in 2007. The cause of the undulation is unclear although recruitment onto the HiLo trial [5] (recruiting from 2007 to 2010) may have acted to increase RAI referrals, while the IoN trial [6] (recruiting from 2012 to 2019) and most significantly changes in referral criteria in the British Thyroid Association guidelines [7] may have acted to temporarily reduce numbers.

The activity prescribed for RAI has shifted over the past 10 years, likely driven by the HiLo trial leading to the widespread use of 1.1 GBq, rather than 3.7 GBq, for low-risk ablation patients. In 2007, the modal activity given for an adult ablation was 3.0 or 3.7 GBq of $^{131}$I [1], in 2011 only four survey respondents indicated that they treated using 1.1 GBq, in 2017 this was true for all 28 centres providing RAI. Twelve centres were able to provide a numerical breakdown of the activities prescribed in 2017 to adult patients receiving ablation (411 patients total) and therapy (168 patients total) as shown in Fig. 3. The activities of $^{131}$I most frequently prescribed for adults were 1.1 GBq followed by 3.7 GBq for ablations, and 5.5 GBq for therapies. RAI is available to paediatrics in all nine centres treating paediatric patients with MRT. Data for paediatric treatments are insufficient to show the distribution of prescribed activities for ablation and therapy but centres indicated that they would prescribe 1.1–3.7 GBq for ablation and 3.7–5.5 GBq for therapy.

Table 1 Number of centres from the 31 surveyed treating adult and paediatric patients with molecular radiotherapy, radiiodine for thyroid carcinoma and $^{131}$I-metaiodobenzylguanidine and peptide receptor radionuclide therapy for neuroendocrine tumours

| MRT | RAI | mIBG | PRRT |
|-----|-----|------|------|
| Adult | 31 | 28 | 15 | 15 |
| Paediatric | 9 | 9 | 3 | 2 |

mIBG, metaiodobenzylguanidine; MRT, molecular radiotherapy; PRRT, peptide receptor radionuclide therapy; RAI, radiiodine.

Table 2 Trial participation in each molecular radiotherapy category within our group

| Category | Number of centres participating | Number of trials |
|----------|---------------------------------|-----------------|
| RAI | 16 | 4 |
| mIBG | 1 | 1 |
| PRRT | 5 | 2 |
| $^{223}$RaCl$_2$ (Xofigo) | 13 | 10 |
| $^{89}$SrCl$_2$ | 1 | 1 |
| Monoclonal antibodies | 4 | 6 |
| SIRT | 14 | 4 |

mIBG, metaiodobenzylguanidine; PRRT, peptide receptor radionuclide therapy; RAI, radiiodine; SIRT, selective internal radionuclide therapy.
NET incidence has risen in the UK [8], as have the overall numbers of MRT treatments for NETs over the past 10 years in our surveyed centres. $^{131}$I-metaiodobenzylguanidine (mIBG) use has steadily declined as shown in Fig. 4, with the number of centres administering remaining relatively steady but generally giving fewer treatments each year, potentially as patients are instead referred for PRRT. Only one clinical trial was reported in our group using $^{131}$I-metaiodobenzylguanidine. However, two forthcoming $^{131}$I-mIBG trials, MiniVan (NCT02914405) and VERITAS (NCT03165292), are aimed at paediatric patients with neuroblastoma. $^{131}$I-mIBG remains an established treatment for neuroblastoma in this cohort, with two surveyed centres providing $^{131}$I-mIBG to paediatrics only.

In contrast with mIBG the use of PRRT for treatment of NETs had grown rapidly from 2007 to 2015 with a sharp decline since 2016 as is visible in Fig. 5. Once dominated by the use of peptides labelled in-house to $^{90}$Y, the widespread availability of prelabelled $^{177}$Lu-dotatate (Lutathera; Advanced Accelerator Application, Saint-Genis-Pouilly, France), has aided a rapid expansion in the use of PRRT. In 2007 only four centres provided PRRT, by 2016 there were a total of 17, of whom five provided $^{90}$Y-labelled peptides and 16 used Lutathera, four using both. From 2007 to 2015, the number of patients treated and treatments given grew almost five-fold. Lutathera was removed from the Cancer Drugs Fund (CDF, https://www.england.nhs.uk/cancer/cdf/) in November 2015 (http://www.parliament.uk), the impact of which is clearly visible in Fig. 5, with the number of Lutathera treatments given in our group falling by 2017 to two-thirds of the number given in 2015. Following positive results of the NETTIR-1 trial [9] Lutathera has recently had approval by the European Medicines Agency and The National Institute for Health and Care Excellence (NICE) for use in treating NETs [10] and a possible rise in treatments is predicted in the coming years.

Palliation of bone pain with MRT was historically mainly limited to $^{89}$Sr-chloride and $^{153}$Sm-EDTMP treating at most 170 patients in the surveyed centres in 2007 as shown in Fig. 6. These treatments have steadily declined in popularity and are now rarely used. The small number administered in 2017 were to patients that were considered unsuitable for Xofigo therapy due to poor health or due to having soft tissue metastases.

Following the positive findings of the ALSYMPCA trial [11], a period of availability on the CDF and NICE approval in 2016 [12] the use of Xofigo has grown rapidly as shown in Fig. 7 and is now the most frequently administered form of MRT for cancer treatment. Xofigo has not only replaced $^{89}$Sr-chloride and $^{153}$Sm-EDTMP but is now used to treat roughly five times as many patients as were treated for bone metastases in 2007. Xofigo also features in the largest number of MRT trials across the survey cohort, including several phase II and
III trials, as shown in Table 2. These trials are broadening the range of patients eligible for this treatment to include not just men with prostate cancer but also breast cancer patients.

It is worth noting that, as Xofigo treatments are given over the course of 6 months, our data on the number of patients are slightly inflated as centres will likely have counted patients starting their course in the previous year as well as those finishing in the next. In the latest survey centres were separately asked for the number of new patients treated in 2017, that is, patients who had their first Xofigo treatment in 2017. Providing that treatments are evenly spread across the year this question should yield a truer reflection of the number of patients. In 2017, our respondents treated 811 ‘new’ patients (compared with the 1021 ‘total’ patients), meaning that in the survey cohort the average Xofigo patient received 4.7 administrations out of the intended 6, most likely due to disease progression or complications rendering the patient unsuitable for further treatment.

MRT treatment for haematological malignancies has remained a small but highly varied area throughout the survey period. The largest number treated in any 1 year was 57 using $^{90}$Y-Zevalin in 2007, whereas other treatments, including three patients treated in 2017 with a $^{227}$Th-labelled agent, have been limited to small numbers from a relatively large number of trials (Table 2). Clinical trials of other monoclonal antibody therapies are now open across six UK centres and cover both paediatric and adult patient populations with haematological malignancies.

The number of SIRT procedures increased rapidly over the survey period as shown in Fig. 8 following a surge in use of $^{90}$Y-SIR-Spheres (SIRTex, Sydney, New South Wales, Australia), and later $^{90}$Y-TheraSpheres (Nordion, Ottawa, Ontario, Canada). Both agents were accompanied by trials in which surveyed centres participated (Table 2). Growth has not been steady however with SIRT being cut from the CDF in 2012, followed by a period of Commissioning through Evaluation between December 2013 and March 2017 [13] during which funding was allocated to 10 centres for SIRT, nine of which are included in this survey. The concluding report of the Commissioning through Evaluation [13] and the FOXFIRE global trial results [14] reflected poorly on SIRT in its current application, chiefly to patients with advanced and heavily pretreated colorectal cancer. In 2017, the use of both SIRT agents decreased.

**Conclusion**

MRT in 2017 was used to treat almost double the number of cancer patients as in 2007, with three and a half times as many treatments. Changes in funding have had a major short-term impact on the use of new therapeutics. However, the greatest changes have arguably been driven by a large number of multicentre phase II and III trials. In the treatment of NETs, the use of $^{131}$I-mIBG has declined, likely due to the rapid increase in the use of PRRT over recent years. PRRT growth has been backed by encouraging trial results, although not without significant upset due to the withdrawal of funding. A period of undulation in treatment numbers and a reduction in activity used to treat thyroid cancer with RAI may be driven by trials and updated guidelines. Unfavourable trial results appear to have had a detrimental impact on the use of SIRT which, despite unsteady funding over the survey period, had been rising. The most significant growth in any MRT category has also been accompanied by the largest number of clinical trials with Xofigo replacing and surpassing existing treatments for bone metastases in an expanding cohort of patients.
The extent of the success of new agents introduced over the past decade, accompanied by clinical trials providing a robust evidence base that most MRTs have historically lacked, are a model for future therapeutics. They give an indication of the potential population that can be reached when agents are backed up, and arguably publicized, by clinical trials, but also demonstrate the resource implications of new and expanding MRTs. Balancing both of these factors requires monitoring data, ideally through a complete and up to date database of UK MRT activity, and highlights the necessity to harness the treatment optimization potential of patient specific dosimetry.

Acknowledgements
The authors acknowledge support from the NIHR RM/ICR Biomedical Research Centre.

Conflicts of interest
There are no conflicts of interest.

References
1 The British Institute of Radiology Molecular Radiotherapy Working Party. BIR report 23 Molecular radiotherapy in the UK: current status and recommendations for further investigation. London, UK: The British Institute of Radiology; 2011.
2 Rojas B, Hooker C, McGowan DR, Guy MJ. Five years of molecular radiotherapy growth in the UK: survey results from 2007 to 2012. Nuc Med Commun 2015; 36:761–765.
3 Rojas B, Hooker C, McGowan DR, Guy MJ, Tipping J. Eight years of growth and change in UK molecular radiotherapy with implications for the future: Internal Dosimetry Users Group survey results from 2007 to 2015. Nuc Med Commun 2017; 38:201–204.
4 Cancer Research UK. Available at: http://www.cancerresearchuk.org. [Accessed 14 November 2018].
5 Mallick U, Harmer C, Yap B, Wadsley J, Moss L, Nicol A, et al. HiLo: multicentre randomized phase III clinical trial of high vs low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer. Paris, France: International Thyroid Congress; 2010.
6 Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network Randomised Trial following HiLo. Clin Oncol 2012; 24:159–161.
7 Perros P, Colley S, Boelkaft E, Evans C, Evans RM, Gerrard GE, et al. British Thyroid Association. Guidelines for the management of thyroid cancer, 3rd edition. Clin Endocrinol (Oxl) 2014; 81 (Suppl 1):1–122.
8 Genus T, Bouvier C, Wong K, Sirrakusanthan R, Rous B, et al. Incidence and prevalence of neuroendocrine tumours in England. Endocrine Abstracts; 2017: 52. OC3.
9 Strosberg J, El-Haddad G, Wolin E, Hendifah A, Yao J, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376:125–135.
10 National Institute for Health and Care Excellence. Technology appraisal guidance [TA539] Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours. London, UK: National Institute for Health and Care Excellence; 2018.
11 Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213–223.
12 National Institute for Health and Care Excellence. Technology appraisal guidance [TA412] Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. London, UK: National Institute for Health and Care Excellence; 2016.
13 White J, Dale M, Morgan H, Sewell B, Carolan-Jones G Commissioning through evaluation: selective internal radiation therapy (SIRT). Evaluation report. Cedar; 2017.
14 Van Hazel GA, Heinemann H, Sharma NK, Findlay MPN, Riche J, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevaciazumab) versus mFOLFOX6 (plus or minus bevaciazumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34:1723–1731.